{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-113986","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2025-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.582015+00:00","generated_at":"2026-05-17T07:02:00.200106+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Iterum shareholders reject say-on-pay, share increase, and equity plan at AGM","bullets":["David Kelly elected Class I director with 10.8M for, 2.8M against, 0.7M abstain, 8.2M broker non-votes.","Say-on-pay failed: 5.4M for (38.5%), 8.4M against, 0.5M abstain.","Share capital increase to $2.6M (add 80M shares) rejected: 6.5M for, 15.8M against.","Equity incentive plan amendment to add 4M shares rejected: 2.5M for, 11.3M against.","Allotment authority and pre-emption opt-out also failed by wide margins."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-113986","json":"https://secwatch.observer/filing/0000950170-25-113986.json","markdown":"https://secwatch.observer/filing/0000950170-25-113986.md","text":"https://secwatch.observer/filing/0000950170-25-113986.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025113986/0000950170-25-113986-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025113986/itrm-20250910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:02:00.200106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}